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Abstract 
 
Traumatic brain injury (TBI) has become a growing area of study as more young people 
exposed to TBI have been documented to exhibit lasting cognitive deficits. Previous 
research indicates that TBI may increase the risk for Alzheimer’s disease (AD) and 
chronic traumatic encephalopathy (CTE). Mechanisms by which these diseases manifest 
after TBI is not well studied. Previous studies have established rat and mouse TBI models 
that often incorporate mutated AD transgenes that results in phenotypes unrepresentative 
of TBI. Our study attempts to validate a more clinically relevant TBI model using 
repeated mild closed-skull controlled cortical impacts on mice expressing the unmutated 
gene that encodes human APP (hAPP), the parent protein of AD-associated Amyloid-beta 
(Aβ) protein, which only produces slightly elevated levels of Aβ in contrast with most 
other transgenic models. We found that impacted hAPP mice exhibit locomotor and 
cognitive deficits as compared to mice that received a sham treatment.   
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Introduction 
What is TBI? 
Traumatic brain injury (TBI) is a growing health concern leading to one million 
hospitalizations every year (Langlois, Rutland-Brown, & Wald, 2006). Almost no 
demographic is left untouched by TBI, as it is a consequence not only of athletic or 
military-related injury, but also of daily life. Within the United States population from 
1995 to 2001, approximately 28% of TBI related hospitalizations were due to falls 
(Langlois et al., 2006). Governmental measures, enacted to maximize safety of motorists, 
such as a legal limit on driving and blood alcohol level and mandatory helmet laws in 
some jurisdictions, have been shown to reduce TBI related hospitalizations, yet still 
another 20% of TBI related hospitalizations are a result of a motor vehicle accident (Chiu 
2007; Langlois et al., 2006). On a country-by-country basis, TBI hospitalizations are more 
frequently reported in low-income nations, perhaps due to more lenient enforcement of 
governmental safety regulations (Roozenbeek, Maas, & Menon, 2013). Within wealthy 
nations, several special populations are at higher risk of sustaining TBI. In recent years, 
one special population, the elderly, seems to have claimed the most TBI victims, likely 
due to falls (Roozenbeek et al., 2013). Other populations such as young adult men with 
high risk-taking behavior and athletes participating in contact sports as well as military 
personnel also tend to have higher risk to suffer TBI (Gardner & Yaffe 2015; Bruns & 
Hauser, 2003). Individuals participating in contact sports appear to have sustained a 
steady increase in the number of reported TBIs from 1998 to 2011 (Selassie, Wilson, 
Pickelsimer, & Voronca, 2013). As other populations exhibit decreases in TBI, it is 
interesting to speculate as to why contact sport athletes have shown increased TBI 
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incidence despite increased safety regulations, such as the National Football League’s 
increasingly strict helmet-to-helmet hitting policies. One popular theory is that with more 
safety regulations, an athlete may play longer with the expectation that certain regulations 
will protect him or her than they actually can (Selassie et al., 2013).  
TBI occurs in many forms, most commonly in the form of mild, closed-head TBI 
(scalp or skull not penetrated or broken), which often occurs as a consequence of falls or 
playing contact sports and is likely highly underreported (Selassie et al., 2013). In many 
cases, mild TBI is suspected to occur chronically, especially in the case of athletes 
(Selassie et al., 2013). Another form of TBI is severe open-head TBI (scalp or skull 
penetrated or broken) which occurs most frequently in motor vehicle accidents 
(Andriessen et al., 2011). Blast related TBI is a form of TBI commonly associated with 
military personnel or individuals working with explosives. Severity of TBI is often 
assessed using the Glasgow Coma Scale (GCS), an assessment given by emergency 
responders. The GCS is composed of a visual element, which assesses pupil reactivity 
and eye movement, a verbal element in which the patient's verbal responsiveness is rated, 
and a motor element, which rates the patient's ability to move. Each component score is 
added up resulting in an estimate of TBI severity in which a GCS score of 3-8 would be 
considered a severe TBI, a moderate TBI would be score between 9-12 while a mild TBI 
would score between 13-15 (Andriessen, Jacobs, & Vos, 2010; Kristman et al., 2014).   
The symptoms of TBI vary widely, even within similar GCS score ranges. 
Symptoms, however, are often broken into two categories, immediate and delayed 
(Marshall et al., 1991). Immediate symptoms last from hours to days and are usually 
reported as cognitive deficits such as amnesia, slurred speech, inability to focus, impaired 
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judgement, visual disturbances, as well as transient motor impairments such as poor 
balance and stumbling (Marshall et al., 1991; Shlosberg, Benifla, Kaufer, & Friedman, 
2010). These symptoms are often attributed to the immediate damage caused by a severe 
head impact (Marshall et al., 1991). When this occurs the injury is often considered a 
concussion, in which brain damage is acquired in the region adjacent to the region of 
contact, and with sufficient force, often causes the brain to receive a countercoup injury 
on the opposite side of the brain. This effect is due to the physics of sudden impacts, 
which cause the brain to reverberate off the inner walls of the cranial cavity with enough 
force to cause damage in multiple points of contact (Ommaya, Grubb, & Naumann 1971). 
The next phase of TBI symptoms have a delayed onset that can occur days to years after 
TBI and last indefinitely. These symptoms may present as disturbances in personality, 
depression, anxiety, and impaired cognition (Ross et al., 2012). Often, these symptoms 
resemble those seen in neurodegenerative diseases such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and chronic traumatic encephalopathy (CTE), however, after 
TBI these symptoms appear at very young ages in comparison to the symptoms of other 
neurodegenerative diseases (McKee et al., 2009; Johnson, Stewart, & Smith, 2012). It is 
suspected that these delayed symptoms are more severe in cases in which a patient has 
received multiple TBIs (Stein, Alvarez, & McKee 2015). 
The delayed symptoms that occur in TBI patients are particularly interesting to 
researchers and healthcare professionals not only because of the clinical similarities to the 
cognitive and behavioral symptoms of neurodegenerative diseases, but also because of the 
highly similar cellular and molecular changes that occur in both TBI patient brains and 
the brains of patients with neurodegenerative diseases (Johnson et al., 2012; McKee et al., 
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2009). At the cellular level, neuronal loss and axonal damage can be seen, especially in 
proximity to where the impact occurred. At the molecular level, researchers have 
speculated on the source of the delayed symptoms and have uncovered numerous 
potential mechanisms that contribute to a TBI patient’s development of 
neuropsychological and physiological impairments reminiscent of those exhibited by 
patients with neurodegenerative diseases (Masel & DeWitt 2010). It appears that 
disruption of the homeostatic mechanisms of the brain are central to the secondary 
damage caused by TBI. One important disease mechanism that contributes to the 
appearance of the secondary symptoms of TBI is pathological breakdown of the blood 
brain barrier (BBB), the barrier made up of tight junctions that separates the central 
nervous system (CNS) from the circulatory system (Korn, Golan, Melamed, Pascual-
Marqui, & Friedman, 2005). After TBI, initial impact may cause a weakening of the BBB 
in the region where the impact occurred due to mechanical stress on vascular tissues, 
which theoretically allows more toxins to enter the CNS resulting in further neuron 
damage or death (Zlokovic, 2008). This process is thought to induce further BBB 
disruption by instigating a positive feedback loop driven by way of an inflammatory 
immune response to combat toxin influx (Shlosberg et al., 2010; Zlokovic, 2008). 
Increasing BBB permeability, however, is not the only potential mechanism that could 
induce an immune response after TBI. Within the CNS, neuroinflammation and reactive 
gliosis may contribute to further neuronal damage (Ziebell & Morganti-Kossmann, 2010). 
This process essentially causes glial cells to become overactive and target not only 
foreign materials, but also healthy endogenous neuronal tissues. Furthermore, it is 
speculated that extracellular levels of glutamate and potassium increase after TBI, which 
AMYLOID-BETA AND REPEATED TBI 
 
 
5 
has been shown to lead to cell death and necrosis by over excitation and increased 
oxidative stress (Reinert et al., 2000). Other research has shown that after TBI, neurons 
become more sensitive to calcium activated processes such as calpain and caspase 
activity, which become hyperactive and induce severe damage to neurons (Beer et al., 
2000). Mitochondrial function also appears to become impaired in response to increases 
in intracellular calcium caused by TBI (Xiong, Gu, Peterson, Muizelaar, & Lee, 1997). In 
addition to TBI related damage causing disrupted homeostatic mechanisms, more forms 
of secondary damage occur as a result of a large influx of Alzheimer’s disease related 
proteins, such as amyloid-beta (Aβ) and tau. When these proteins appear in higher 
quantities and misfolded configurations, they take a toll on the cognition of patients. 
Interestingly, many TBI patient brains are full of a wide distribution of Aβ deposits 
(Roberts et al., 1994). Other studies have uncovered evidence that hyperphosphorylated 
tau protein spreads throughout the brain contributing further to the deterioration of TBI 
patients’ days to weeks after initial injury. TBI patient brains have been examined in 
multiple studies and were unsurprisingly riddled with tau tangles and Aβ deposits 
(Magnoni et al., 2011; Johnson et al., 2012).  
 
Neurodegenerative Diseases Associated with TBI 
One of the most important conclusions of research on TBI today is the close 
relationship between TBI and neurodegenerative diseases, namely, AD and CTE. 
According to the World Health Organization AD is the most common form of dementia 
in the world (World Health Organization, 2017). AD was first described by Dr. Alois 
Alzheimer in 1907 after examining the brains of deceased elderly patients who exhibited 
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similar neuropsychiatric impairments such as decreased memory and cognition as well as 
personality changes and apparent psychosis (Alzheimer, 1911). When examining patient 
brain tissue, Alzheimer discovered Aβ protein deposits and neurofibrillary tau tangles, 
referred to today as the “hallmarks” of AD (Alzheimer, 1911). Understanding the nature 
of the proteins associated with the pathogenesis of AD is key to the development of 
treatments for both AD and TBI among other dementias because these diseases all share 
misfolded Aβ and neurofibrillary tau tangles in common. The frontline treatment of AD 
revolves around targeting the initial symptoms that occur during the early stages of 
clinical presentation of the disease, memory and other cognitive deficits. This approach 
capitalizes on “boosting” the activity of a major neurotransmitter system associated with 
memory known as the cholinergic system (Terry & Buccafusco 2003). In AD patients, 
research has shown that there is decreased synthesis of the neurotransmitter acetylcholine, 
which plays a major role in the cholinergic system by stimulating cognitive activity. To 
take advantage of this knowledge, drugs that boost acetylcholine production or reduce its 
degradation are often administered (Terry & Buccafusco 2003). This frontline treatment, 
however, appears to allow for only limited improvement as the cholinergic neurons that 
produce this neurotransmitter eventually deteriorate as a result of the dysfunctions caused 
by Aβ and neurofibrillary tau tangles. Today, the cholinergic hypothesis is largely rejected 
as the primary cause of worsening symptoms of AD patients as the root of the disease 
likely lies in the spread of neurofibrillary tau tangles and the buildup of Aβ plaques. 
Research on these two proteins has given rise to the leading hypotheses to explain how 
and why AD manifests and progresses, known as the Tau hypothesis and the Amyloid 
cascade hypothesis. These theories are often disputed over as it is debated which precedes 
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the other, hyperphosphorylation of the structural protein tau which leads to Aβ misfolding 
and aggregation, or misfolding and aggregation of Aβ which leads to 
hyperphosphorylation of tau. Regardless of which pathogenic process occurs first, both 
are detectable in AD patient brains and both contribute to brain cell death.  
To examine both the tau and amyloid hypotheses more closely, we must first 
understand the importance of each protein in the healthy brain. Most notably, tau proteins 
are an important element of microtubules, structural proteins that allow transport of 
nutrients and essential proteins from the cell body to peripheral locations of the cell such 
as the terminal button where signal transmission occurs (Ballatore, Lee, & Trojanowski, 
2007). The Aβ protein is slightly more elusive in its normal function. Studies have shown 
that Aβ may play a role in maintaining neuronal excitation by preventing over activity 
(Palop & Mucke, 2010). When these proteins function improperly, many problems occur 
within the cell. In the case of the tau protein, misfolded tau proteins form neurofibrillary 
tangles (Ballatore et al., 2007). These misfolded proteins comprise the normal structure of 
microtubules and impair cellular transport. This often leads to reduced nutrient trafficking 
and cell death (Ballatore et al., 2007). When the Aβ protein misfolds, it clumps together 
with other misfolded Aβ proteins to form oligomers and fibrils, which make up the 
majority of the extracellular Aβ plaques seen in deceased patient brains (Johnson et al., 
2012). When this occurs, synaptic connections have been reported to deteriorate, leading 
to cognitive decline (Cleary et al., 2005). 
Another neurodegenerative disease that is closely related to TBI is the condition 
known as CTE, or chronic traumatic encephalopathy. This disease is thought to emerge 
after years of repetitive head injury. The outward symptoms of CTE present as very 
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similar to AD; they are often behavioral, most commonly yielding impairments in 
cognitive abilities and alterations in personality (Stern et al. 2013). This disease, similarly 
to AD, is progressive in nature. It was first described in the landmark study by Omalu et 
al., (2005), of a 50-year-old American Football player who had exhibited cognitive and 
emotional deficits as well as some symptoms of neurodegeneration related parkinsonism. 
This study paved the way for formation of a link between TBI and accelerated 
neurodegeneration. Early stages of CTE consist of headaches and the inability to 
concentrate, moderate stages are diagnosed by presence of memory problems, emotional 
disturbances, and impulsive behavior, and late stages often include dementia, problems 
with movement, and severe depression (Stern et al., 2013). CTE is often described as a 
tauopathy, due to the extensive tau tangles that can be detected in the brain of a patient 
post-mortem (Stern et al., 2011). These tau tangles often follow a unique distribution that 
extends around the sulci of the brain (Stern et al., 2011). In one study of adolescent brain 
tissue donated post-mortem, two of four brains exhibited widespread tau pathology along 
the sulci of the brain, consistent with previous findings (Tagge et al., 2017). Despite the 
presence of tau tangles as the major defining feature of CTE, Aβ plaques are also present 
in patient brain tissue and both appeared in greater quantities than could be attributed to 
natural aging (Omalu et al., 2005). Recent research has shown that despite tau 
hyperphosphorylation constituting a major component of CTE-like diseases, Aβ 
misfolding and accumulation appears to occur upstream of tau dysfunction (Bloom, 2014; 
Johnson, Stewart, & Smith, 2010). In light of this, my study focused on the impairments 
caused by the misfolded and aggregation prone Aβ protein after TBI.  
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A Closer Look at Amyloid-Beta 
Aβ is a small protein fragment cleaved from the membrane-bound amyloid 
precursor protein (APP). In disease scenarios, Aβ is cleaved to form a slightly larger 
fragment (42 amino acid) which has a higher affinity to accumulate and form Aβ plaques 
in the extracellular matrix between neurons (Esler et al., 2000). Whether plaque 
formation serves as a defense mechanism against toxic misfolded Aβ from contaminating 
other Aβ proteins or plaque formation itself is harmful to cells is still not well understood. 
Accumulation of Aβ fragments is thought to occur naturally and harmlessly due to regular 
cellular processes that regulate Aβ levels (Marr et al., 2003; Marr & Hafez, 2014). 
Certain endopeptidases, such as neprilysin, have been shown to be responsible for the 
degradation of Aβ, preventing excess accumulation and plaque formation, thereby 
maintaining a healthy brain (Marr et al., 2003; Marr & Hafez, 2014). Both, Aβ and APP, 
have relatively unknown functions in the healthy brain. As mentioned before, though 
elusive, some studies have shown that the function of APP and Aβ is involved in 
regulation of neuronal signaling and synaptic transmission (Kamenetz et al., 2003). The 
cause of neurodegeneration that occurs in AD is most commonly attributed to the amyloid 
cascade hypothesis, which states that excess Aβ accumulation is neurotoxic and initiates a 
“cascade” of other toxic biochemical changes (Karran, Mercken, & Strooper, 2011). 
When neurodegeneration occurs, it is often a result of mutations in APP, or enzymes that 
process it, that make the protein more susceptible to be cleaved improperly, yielding the 
formation of the slightly larger, more toxic form of the protein, Aβ42 (Selkoe, 1999). 
This form of Aβ has been reported to be more prone to accumulation and more difficult 
for endogenous endopeptidases to clear, in comparison to the more neutral and smaller 
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form, Aβ40, which is produced after normal secretase interaction with APP, resulting in 
neurotoxicity (Jarrett & Lansbury, 1993; Shoji et al., 1992). In TBI, similar mechanisms 
appear to be at play, however, it is not well understood whether endopeptidase activity is 
impaired or Aβ production is upregulated or a combination of these factors lead to plaque 
formation and behavioral and other neuropsychiatric impairments. To learn more about 
aberrant Aβ activity after TBI, researchers have used several methods to model TBI and 
discover more about the disease process.  
 
Modelling TBI 
Since interest in TBI and the physiological processes have increased in recent 
years, several methods of modelling this condition have been developed. Due to cost and 
ethical standards, rodents are used more commonly that larger mammals to model human 
using several experimental procedures in which impacts are delivered to the skull to 
induce a TBI. Fluid percussion injury (FPI) models induce brain injury that are clinically 
similar to human TBI without skull fracture in terms of animal behavior and observable 
damage to brain tissue (Xiong, Mahmood, & Chopp, 2013). To induce TBI using this 
system, a high-pressure fluid pulse is applied directly to brain tissue following a 
craniotomy procedure (Xiong et al., 2013). This may be seen as a complication that 
creates too much distance between the model and human cases. FPI models are 
characterized based on the location of the craniotomy where researchers intend to induce 
TBI (Xiong, 2013). The most commonly used FPI model induces TBI lateral to the 
midline of the brain, causing similar degrees of local and diffuse damage as seen in 
human TBI (Xiong et al., 2013). Penetrating ballistic brain injury (PBBI) models are used 
to mimic gunshot and explosion related TBI with direct damage to brain tissue via 
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penetration of skull. These models also model the effects of intracranial pressure 
associated with damage caused by explosions. Weight drop models are also used to 
mimic the effects of open skull and closed skull TBI by dropping weights onto the skull 
(Xiong et al., 2013). Modeling TBI with controlled cortical impact (CCI) devices, which 
generally utilize air-powered or electromagnets to deliver an impact, is advantageous in 
that these devices can be programmed to deliver impacts at specific velocities and force 
allowing for precise control over severity and location of impact (Xiong et al., 2013). 
Furthermore, the TBI model systems mentioned often include use of a mild TBI paradigm 
in which injuries are produced to mimic mild concussion or sub-concussive injury (Xiong 
et al., 2013). Mild TBI paradigms are often used to develop models of chronic mild head 
injury. These chronic models have gained popularity due to the ability to simulate injuries 
humans commonly acquire when engaged in athletic activities that may cause individuals 
to be chronically exposed to mild concussion or sub-concussive injury (Xiong et al., 
2013). 
The animal models of TBI mentioned above are used extensively across labs in 
the field of TBI, however, they are not without their limitations. Much of TBI research is 
done on rodents due to low cost and availability, however, it should be noted that rodents 
do not perfectly model humans in terms of brain function and recovery after TBI. One 
example of a major difference between human and rodent brains is that the rodent brain 
lacks gyri and sulci, the crevices and folds seen on the surface of the human brain (Xiong 
et al., 2013). This difference in brain complexity makes it more difficult to draw direct 
parallels between TBI damage in humans versus TBI in rodents. To combat this, 
modifying rodent genomes to artificially express human genes using various knock-in 
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models, can reveal more insight into the mechanisms behind TBI. Studies with rodents 
are essential to develop a broad picture of the TBI disease process to pave the way for 
experimentation on “higher” animals that more closely model human physiology.      
The model used in this study uses a chronic mild TBI paradigm on genetically 
modified mice. Our transgenic mice express a copy of the healthy human APP (hAPP) 
gene in addition to their own endogenous APP. The introduction of the hAPP transgene 
provides an advantage in the current model over previous systems as it allows for only a 
slight increase in Aβ formation, as opposed to many other transgenic models that 
drastically overproduce Aβ, making it more clinically relevant. Additionally, hAPP mice 
do not display deficits in behavior from non-transgenic mice, therefore allowing for 
observations of how TBI interacts with APP and Aβ. 
 
Gap in Knowledge  
The mechanism behind how TBI leads to persistent cognitive deficits and 
increases likelihood development of AD-like neuropathology and is not well understood, 
as it is unlikely that dysfunction of only one system leads to pathology. The present study 
was designed to investigate the activity of Aβ when TBI occurs and how it is related to 
behavioral changes in chronically impacted mice. 
 
 
Hypothesis 1: Behavioral deficits indicate TBI in non-transgenic and hAPP mice 
 Concussions in humans are often accompanied by transient decline in motor 
performance and longer lasting cognitive impairments such as poor memory and 
increased anxiety. Our model attempts to mimic these deficits using repeated CCI on 
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mice. We hypothesized that repeated mild TBI analogous to human repeated mild TBI 
can be confirmed in our mice by measuring motor performance using the rotarod 
assessment and open field test, and cognitive impairments using Morris Water Maze 
(MWM), Novel object recognition (NOR) tests, and an open field test for anxiety. We 
predicted that all mice receiving impacts would perform more poorly on motor and 
cognitive behavioral tests as compared to sham mice. Furthermore, we predicted that our 
hAPP mice would show greater deficits as compared to our wild-type mice that received 
impacts.    
 
Hypothesis 2: Altered biochemistry after TBI  
Many neuropathological changes have been reported to occur following multiple 
TBIs ranging from reactive gliosis to tau and Aβ accumulation. In the current study, we 
predicted that impacted mice would exhibit changes in brain tissue reminiscent of tissue 
changes seen in human TBI, AD, and CTE. Furthermore, we hypothesized that after 
repeated TBIs greater amounts of Aβ42 would be detectable in our hAPP mice as 
compared to our non-transgenic mice. We also predicted that our impacted non-
transgenic mice would have greater relative Aβ42 levels as compared to mice that 
received a sham procedure. 
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Method 
Transgenic Mice 
Wild-type C57BL/6J mice and transgenic mice were obtained from Jackson 
Laboratories carrying entire gene locus of the wild-type form of the human amyloid 
precursor protein by the method of Lamb et. al, 1993. Animals were group housed under 
standard laboratory conditions with ad libitum access to food and water and 12-hour 
light-dark cycles. All animals were handled in accordance to IRB ethical standards.   
 
Experimental Timeline 
Animals were administered impacts or sham procedures chronically every other 
day over the course of 9 days (5 total impacts). Two hours after the final impact or sham 
procedure the rotarod assessment was conducted as well as the open field test. 24-hours 
post final impact or sham procedure another rotarod assessment was conducted in 
addition to the habituation phase of the NOR test. Two days post final impact or sham 
procedure the NOR test was conducted. Five days post final impact or sham procedure 
began the MWM spatial memory acquisition period in which animals were tested over the 
course of five days (see Figure 1). 
  
Multiple Mild Controlled Cortical Impact and Sham Surgery 
To induce repeated mild TBI, Leica Biosystems electromagnet powered Impact 
One CCI device used on experimental mice. Mice were first anesthetized using 2% 
isoflurane flow rate. Topical anesthetic Novocain was then applied to shaved scalp. 
Impacts were delivered at 5m/s to surface of skull above bregma with a depth of 2.2mm 
using a stereotax. Immediately following impact, meloxicam was administered. Mice 
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were then returned to home cages and monitored until full recovery from anesthesia. Mice 
receiving sham procedures were anesthetized with 2% isoflurane flow rate for 15 minutes 
then administered meloxicam and returned to home cage for recovery. This process was 
repeated for five total impacts or sham sessions with administration of treatment every 
other day per mouse.    
 
Rotarod Assessment 
Locomotor skills of mice were tested before and after impacts and sham 
treatment. Pre-training consisted of six morning trials and six afternoon trials. Between 
every two trials mice were given a fifteen-minute rest period in home cages. Trials ended 
when the animal fell from the apparatus (no longer than 180 seconds). The total run time 
on the final three rotarod trials were used to establish a baseline measure of locomotor 
abilities. Mice were then given three test trials on the rotarod apparatus 2 hours and 24 
hours after the final impact or sham treatment to analyze changes in locomotor 
performance.  
 
Open Field and Novel Object Recognition 
After the final impact or sham treatment mice were placed in a 61X61cm “open 
field box” as another measure of locomotor skills and anxiety. TSE VideoMot2 software 
was used to track and record distance traveled as well as time spent in the center region 
and periphery of the open field during a 30-minute open field-testing period. Total path 
length to measure locomotion as well as time spent in the center and periphery of open 
field to measure anxiety were recorded. One day following open field-testing the 
habituation phase of the novel object recognition test was performed using the same 
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61X61cm box and TSE VideoMot2 software. Habituation phase consisted of placing two 
identical objects equidistant from each other and the sides of the box. Animals were 
placed individually into the box and given 7 minutes to become familiar with the objects. 
24-hours later the test phase of novel object recognition was run. A novel object replaced 
one of the familiar objects (determined by coin flip or random number generator for each 
trial) and mice were given 7 minutes to inspect the environment with both the familiar 
and novel object present. Time spent inspecting objects were recorded. More time spent 
investigating the familiar object as compared to the novel object indicated impaired 
memory. The objects and open field box used for open field-testing and novel object 
testing was cleaned using 70% ethanol between each trial. 
 
Morris Water Maze 
As another measure of learning and spatial memory, mice were tested in a water 
maze. An approximately 300-gallon tub was filled with water mixed with non-toxic white 
paint to hide a platform. Over the course of five training sessions (four trials per day), 
mice were tested on their ability to find the hidden platform. Mice were placed in the tub 
at one of 3 entry points (determined randomly) during each of the four trials per session 
and given one minute to reach the hidden platform. Path analysis and time to reach 
platform was recorded using TSE VideoMot2 software.  
 
Perfusion and Brain Dissection 
Mice were perfused with PFA after being anesthetized with intraperitoneal 
administration of urethane. After perfusion craniotomy was performed. The removed 
brain was cut along the mid-sagittal axis to separate hemispheres. One hemisphere was 
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stored in 4% PFA for 24 hours then transferred to a 30% sucrose solution. The remaining 
hemisphere was dissected further to obtain the brainstem, cortex, hippocampus, and 
cerebellum. Each dissected brain region was stored in its own vial at -80 degrees C.   
Amyloid Beta Quantitation 
Mouse cerebellums were individually homogenized. Protein levels relative to total 
tissue was determined using a Wako Chemicals BCA protein assay. A Wako Chemicals 
ELISA was performed to determine relative levels of amyloid beta in each sample.  
Statistical Analysis 
All 2 (hAPP versus non-transgenic) by 2 (impact versus sham procedure) 
comparisons were generated using two-way analysis of variance statistical tests in IBM 
SPSS Statistics 24 and Microsoft Excel 2016. Additional analysis using student’s t-tests 
and Bonferroni post hoc tests were conducted using IBM SPSS Statistics 24 and 
Microsoft Excel 2016.  
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Results 
Behavior 
Multiple behavioral tests were employed to assess mouse performance after 
receiving multiple impacts. Statistics were generated using Microsoft Excel 2016 and 
IBM SPSS Statistics 24. The rotarod assessment was used to measure changes in total run 
time to elucidate locomotor function of all groups of mice post impact or sham procedure. 
Measurements were analyzed at two time points post final impact or sham procedure at 2 
hours and 24 hours. Scores were based on deviation from baseline performance and 
ranged from run times of 11.77 to 139.47 seconds (R=127.70) at the 2-hour time point 
with a Mean of 95.87 seconds (SD=27.83). At the 24-hour measurement scores ranged 
from 9.03 to 169.25 seconds (R=160.22) with a Mean score of 97.46 seconds (SD= 
34.39). Two-way analysis of variance comparing treatment (impacted versus sham) by 
genotype (non-transgenic versus hAPP mice) revealed a significant effect of treatment 
(impact versus sham procedure) at the 2-hour test (F(1, 39)=10.744, p=.002, 𝜂p2=.230). 
Upon further analysis using student's t-tests, significant differences in rotarod 
performance within the hAPP genotype was detected as shown in Figure 2A 
(t(9.036)=2.719, p=.024). This indicated that hAPP mice that received impacts fell off 
rotarod apparatus sooner than non-impacted hAPP mice (M=73.9, SD=36.2 seconds). 
Within the non-transgenic group no statistically significant differences in performance 
could be detected at the 2-hour rotarod assessment (t(18.077)=1.736, p=.099). At the 24-
hour rotarod assessment the significant main effect of treatment (impact versus sham) 
persisted as revealed by two-way ANOVA (F(1, 40)=12.181, p=.001, 𝜂p2=.248). 
Student’s t-tests were used again to detect differences in rotarod performance across 
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genotypes. These tests revealed a significant difference between impacted hAPP mice and 
hAPP sham mice (t(18)=3.127, p=.006). This showed that impacted hAPP mice 
continued to fall off the rotarod apparatus significantly earlier (M=72.2, SD=35.0 
seconds) than hAPP sham mice (M=110.9, SD=17.5 seconds) 24 hours after the animals 
received the final impact or sham procedure (see Figure 2B). Statistical analysis of the 
non-transgenic group failed to detect significant differences in rotarod performance 
between impacted and sham mice at the 24-hour rotarod assessment (t(19)=1.934, 
p=.068).   
The open field test was used as another method of assessment of locomotion by 
measurement of distance traveled post-impact or sham procedures. A two-way ANOVA 
comparing treatment (impacted versus sham) by genotype (non-transgenic versus hAPP 
mice) revealed a significant main effect of treatment (F(1, 39)=6.503, p=.015, 𝜂p2=.153). 
This indicated that impacted animals traveled a shorter distance in the open field as 
compared to animals that received sham procedures (see Figure 3A). Further analysis 
revealed that impacted hAPP mice traveled a significantly shorter distance (M=7718.2, 
SD=2139.7 cm) than hAPP sham mice (M=10955.6, SD=2603.6 cm) as determined by a 
student’s independent samples t-test (t(17)=2.974, p=.009). Independent samples t-tests 
comparing non-transgenic mice failed to detect significant differences in distance traveled 
(t(19)=.698, p=.494). To examine anxiety more closely, time spent in the center region of 
the open field was measured. A two-way ANOVA comparing treatment by genotype on 
time spent in the center region failed to reveal a significant effect of treatment (F(1, 
35)=.042, p=.839, 𝜂p2=.001), genotype (F(1, 35)=2.114, p=.155, 𝜂p2=.057), or treatment 
by genotype interaction (F(1, 35)=.708, p=.406, 𝜂p2=.020). This shows that mice across 
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treatments and genotypes did not differ in terms of time spent in the center of the open 
field (see Figure 3B).    
Behavioral tests were also used to detect cognitive changes in post impact and 
post sham procedure mice. We used the novel object recognition (NOR) test to assess 
mouse memory by measuring the percent time spent inspecting a novel object as 
compared to a familiar object (see Figure 4). A two-way ANOVA comparing treatment 
(impacted versus sham) by genotype (non-transgenic versus hAPP mice) failed to reveal a 
significant main effect of genotype (F(1, 39)=.201 p=.656, 𝜂p2=.006), treatment (F(1, 
39)=.106, p=.746, 𝜂p2=.003), or a significant interaction (F(1, 39)=.971, p=.331, 
𝜂p2=0.026). This shows that no statistically significant differences across treatment or 
genotype could be detected.  
As a measure of learning and spatial memory, we trained mice in the Morris water 
maze (MWM) over a 5-day acquisition period (see Figure 5). Each day of the acquisition 
period time to reach the hidden platform was measured. A repeated measures two-way 
ANOVA of treatment (impact versus sham) by genotype (hAPP versus non-transgenic) 
over the course of five days revealed a significant main effect of treatment (F(1, 
36)=8.578, p=.006, 𝜂p2=.192) indicating that sham mice reached the hidden platform 
more quickly than impacted mice. Bonferroni post-hoc tests of simple main effects 
revealed that impacted hAPP mice were significantly slower at reaching the platform 
(M=43.27, SD=13.70 seconds) as compared to hAPP sham mice (M=23.94, SD=12.11 
seconds). For non-transgenic animals, however, there were no significant differences over 
the five-day acquisition training period. A significant treatment by genotype interaction 
was also detected (F(1, 36)=4.475, p=.041, 𝜂p2=.111). When analyzing day 5 specifically, 
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the final day of acquisition trials, as a measure of spatial learning, a two-way ANOVA 
revealed a significant main effect of treatment on time to reach the hidden platform (F(1, 
39)=13.238, p=.001, 𝜂p2=.269). Further analysis revealed that within the non-transgenic 
group, mice receiving impacts took longer (M=41.7, SD=16.0 seconds) to reach the 
hidden platform than sham mice (M=28.1, SD=14.9 seconds). Additionally, hAPP mice 
that received impacts also took longer to reach the hidden platform (M=43.3, SD=13.7 
seconds) as compared to sham hAPP mice (M=23.9, SD=12.1 seconds). Bonferroni post 
hoc testing revealed these differences in mean time to platform were significant between 
impacted and sham mice within the non-transgenic (p=.041) and hAPP groups (p=.005). 
In another assessment of spatial memory using the water maze, we measured the percent 
time mice spent in the quadrant where the hidden platform had been in probe test 1, 24 
hours after the final acquisition trial and probe test 2, 72 hours after the final acquisition 
trial. A two-way ANOVA was used to analyze the results of probe test 1. Analysis 
revealed a significant effect of genotype (F(1, 39)=7.363, p=.010, 𝜂p2=.170) and a 
significant effect of treatment (F(1, 39)=8.160, p=.007, 𝜂p2=.185) in addition to a 
significant interaction of genotype by interaction on time spent in the correct quadrant 
(F(1, 39)=4.962, p=.032, 𝜂p2=.121). Further analysis using Bonferroni post hoc testing 
revealed a significant mean difference in time spent in the correct quadrant within the 
hAPP genotype (p=.001). This indicated hAPP sham mice remained in the correct 
quadrant significantly longer (M=.370, SD=0.089) than impacted hAPP mice (M=.207, 
SD=.096), as shown in Figure 6A. Post hoc tests also showed that within the sham 
treatment group, hAPP mice remained in the correct quadrant longer (M=.370, SD=.089) 
than the non-transgenic sham mice (M=.211, SD=.108), indicating improved memory of 
AMYLOID-BETA AND REPEATED TBI 
 
 
22 
hAPP mice (p=.002). A two-way ANOVA was also used to analyze the results of probe 
test 2, in which significant main effects of genotype (F(1, 39)=4.782, p=.035, 𝜂p2=.117) 
and treatment (F(1, 39)=9.679, p=.004, 𝜂p2=.212) were readily detectable (see Figure 6B). 
Bonferroni post hoc testing revealed a significant mean difference in time spent in the 
correct quadrant between sham (M=.357, SD=.091) and impacted mice (M=.216, 
SD=.087) within the hAPP genotype. This showed that hAPP mice that received impacts 
did not remain in the proper quadrant as long as sham hAPP mice (p=.011). When 
analyzing the effect of treatment, post hoc tests were unable to detect a significant mean 
difference between non-transgenic (M=.253, SD=.156) versus hAPP mice (M=.357, 
SD=.091) that received sham procedures in time spent in the correct quadrant (p=.055). 
 
Biochemistry 
To analyze biochemical differences between non-transgenic and hAPP mice that 
received either impacts or sham procedures an Aβ-42 ELISA was performed on mouse 
cerebellums. A two-way analysis of variance test comparing treatment by genotype 
revealed no significant interaction or main effects of treatment by genotype on relative Aβ 
levels. However, moderate effect sizes were detected for a simple main effect of genotype 
(𝜂p2=.089) and treatment (𝜂p2=.098), suggesting further analysis using statistical tests with 
increased power was necessary. Initial statistical analysis revealed no statistically 
significant differences in relative Aβ42 levels across cerebellar tissue from all groups. 
However, moderate effect sizes and higher levels of Aβ42 detected in the animals that 
received impacts as compared to sham mice, suggested that an effect would be detectable 
with increased statistical power. This prompted use of independent samples t-tests to 
compare the effects of impacts on mouse brain tissue within genotypes. This revealed that 
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hAPP mice that received impacts had significantly higher relative amounts of the Aβ 
protein (M=11.88, SD=3.44) as compared to hAPP sham mice (M=9.26, SD=1.11) as 
determined by a student’s independent samples t-test (t(17)=2.175, p=.044). Non-
transgenic impacted mice and sham mice did not differ significantly in relative Aβ levels 
(see Figure 7).  
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Discussion 
We hypothesized that repeated CCI on hAPP mice would yield a model of human 
mild TBI using several behavioral tests. We expected impacted mice, specifically those 
with the hAPP transgene, to perform more poorly on locomotor assessments transiently as 
compared to sham mice in addition to performing more poorly on cognitive tasks such as 
a novel object recognition task and the Morris water maze. Additionally, we hypothesized 
that impacted hAPP mouse brain tissue would exhibit a profile reminiscent of brain tissue 
from TBI, AD, and CTE patients, specifically in terms of level of Aβ accumulation in 
comparison to sham control groups. Our findings supported our hypothesis that 
chronically impacted hAPP mice could model some behavioral aspects of mild TBI or 
concussion related to the associated deficits in motor and memory performance. Our 
findings in biochemical experiments revealed trends in Aβ deposition levels to lend 
support to our second hypothesis that chronically impacted hAPP animals, as compared to 
non-impacted animals, would display similar histological changes seen in cases of human 
TBI, CTE, and AD. 
 
Behavior 
Transgenic hAPP mice that received multiple impacts performed as expected on 
the rotarod assessment at two-hours post final impact. These mice showed a clear 
impairment in their ability to remain on the rotarod apparatus for as long as the control 
groups of mice at the 2-hour time point (see Figure 2A) indicating that impacted hAPP 
mice developed motor impairment after impacts. The observed effect of transient loss of 
motor coordination is similar to what has been reported to occur in human cases of TBI, 
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offering promise to the validity of this paradigm’s potential as a TBI model. Furthermore, 
impacted hAPP mice continued to show marked impairments at the 24-hour time point on 
the rotarod assessment. This result was not entirely expected as many cases of mild TBI 
in humans show recovery of motor skills around 24-hours post-injury (Guskiewicz, 
2011). Cases of human TBI in which motor deficits persist beyond 24-hours are often 
indicative of a more severe case of TBI or damage to specific brain structures involved in 
balance and movement (Guskiewicz, 2011). However, high amounts of variation exist 
among cases as location of impact may cause differing degrees of impairment in various 
behavioral and cognitive skills (Szczepanski & Knight 2014). Similarly, though 
statistically nonsignificant, the effect of impacts on non-transgenic mice appeared to 
cause a reduction in total time impacted non-transgenic mice were able to remain on the 
rotarod apparatus as compared to sham mice at both the 2-hour and 24-hour time points 
(see Figure 2B).  
Mice that received the hAPP transgene in addition to multiple impacts performed 
significantly differently in the open field test as compared to non-impacted hAPP mice 
(see Figure 3A). Total distance traveled in the open field was used to measure the 
locomotor behavior of mice within the open field. Impacted hAPP mice ambulated in the 
open field significantly less than non-impacted hAPP mice, indicating deficits in 
locomotion (see Figure 3A). The open field test was also used as a measure of anxiety by 
recording the time spent along the edges of the open field (anxious behavior) and time 
spent in the center of the open field (bold, exploratory behavior) in accordance to 
historical observations of rodent behavior (Lister, 1990). We found no statistically 
significant differences on anxiety behavior after TBI across all groups using this measure 
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(see Figure 3B). The result of our anxiety measure contrasts with some literature that 
have documented pronounced decreases in exploratory behavior in rodents after receiving 
TBI, indicating that head injury may increase anxiety (Vink, O’Connor, Nimmo, & 
Heath, 2003). However, other studies have presented results that have shown no 
significant differences between impacted or sham animals in time spent in the center of 
the open field in agreement with what our study has shown (Pullela et al., 2006). In 
general, the open field test is more often used solely as a locomotor assessment as other 
tests, such as the elevated plus maze, appear to measure anxiety in rodents more reliably 
(Pullela et al., 2006; Lusardi, Lytle, Szybala, & Boison 2012; Lister 1990). 
In behavioral assessments of cognition, we were able to show similarities between 
our mouse model and the effects detected in human TBI. Most notably, we detected 
abnormalities in impacted mice and their ability to perform in the MWM, a test of spatial 
memory and learning. Non-impacted mice, both non-transgenic and hAPP mice, 
consistently improved their time to reach the hidden platform over the five-day 
acquisition training period (see Figure 5). By the fifth day of MWM acquisition trials, 
impacted hAPP mice demonstrated significantly impaired ability to locate the hidden 
platform as compared to sham hAPP mice. This result is a clear indication that impacted 
mice develop impairments in learning and spatial memory which is in line with 
observations of human TBI patients, and other rodent TBI models, as it is often 
documented that lasting cognitive deficits can occur as a result of TBI, supporting our 
hypothesis (Mouzon et al., 2012; Guskiewicz 2011; Pullela et al., 2006). Furthermore, 
probe tests 1 and 2 show impaired memory in impacted animals (see Figure 6). 
Interestingly, sham hAPP mice seemed to perform markedly better in the MWM than 
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non-transgenic sham mice. One potential explanation for this finding is that a modest 
increase in normal Aβ within a certain window may actually improve cognition due to 
Aβ’s alleged role in cell-to-cell communication (Abramov et al., 2009).  
In another assessment of rodent memory, the NOR test, we were unable to detect 
any significant effects or interaction of genotype and impact versus sham treatment 
condition. We expected to see non-impacted animals to spend more time investigating a 
novel object as compared to a familiar object. This effect is commonly seen when an 
animal demonstrates typical memory (Ennaceur & Delacour, 1988). Our mice failed to 
exhibit typical behavioral responses in the NOR test making this measure unable to 
support our hypothesis that impacted hAPP mice would demonstrate the highest level of 
memory impairment out of all the test conditions. This result was unexpected and does 
not conform to other TBI studies that have used this measure (Prins, Hales, Reger, Giza, 
& Hovda, 2010; Wakade, Sukumari-Ramesh, Laird, Dhandapani, & Vender, 2010; 
Biegon et al., 2004). Failure of normal, non-transgenic mice to show preference of the 
novel object may be an indication of a problem in methodology.  
In summary, the deficits detected between impacted and non-impacted mice 
across genotypes may indicate that the slight elevation in baseline Aβ production caused 
by the introduction of the hAPP gene in conjunction with repeated mild TBIs may have 
been enough to override normal mechanisms of Aβ clearance, leading to accumulation 
and increased CTE-like pathology. 
 
Biochemistry 
In a biochemical experiment, an Aβ42 enzyme-linked immunosorbent assay 
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(ELISA) was used to measure the relative levels of Aβ42, the form of Aβ that is more 
likely to aggregate, in brain tissue dissected from experimental mice. The cerebellum was 
processed and analyzed specifically. We expected to find higher levels of Aβ42 in the 
cerebellar tissue of hAPP mice that received impacts and, to a lesser degree, in non-
transgenic mice that received impacts as compared to sham procedure control groups. 
This was expected due to the small increase in Aβ that would theoretically occur in mice 
engineered to carry the hAPP gene in addition to their endogenous APP. Furthermore, 
results from behavioral tests seemed to strongly suggest that impacted hAPP mice 
performed with the greatest impairments in locomotion and cognition, leading us to 
suspect that their biochemical profile would contain an elevated level of proteins 
associated with the demonstrated deficits. After analysis we were able to detect 
significantly higher relative levels of Aβ42 in hAPP impacted mice as compared to hAPP 
sham mice (see Figure 7). This seems to indicate that multiple TBIs may have altered 
mechanisms behind APP processing and or Aβ clearance which likely lead to behavioral 
deficits observed previously. Because of this finding it is even more pertinent to analyze 
the cortex, hippocampus, and brainstem, of our mice as significant differences in Aβ42 
levels may be more or less detectable in specific brain regions after TBI (Tran, Sanchez, 
Esparza, & Brody, 2011). 
 
Limitations and Future Research 
The limitations of the current study should also be considered. It should be noted 
that a complicating factor of many TBI studies is difficulty achieving consistency. Even 
with specialized equipment and such as a CCI device, which is known to improve 
AMYLOID-BETA AND REPEATED TBI 
 
 
29 
consistency of impacts, it is unlikely that all subjects received identical injuries. 
Additionally, results of our NOR test were inconclusive as our control mice failed to 
exhibit typical behavior of preference to the novel object, indicating a potential 
methodological problem. These factors may include heightened anxiety or lingering scent 
of other mice on and around the objects despite attempts to control this such as with 
vigorous cleaning with 70% ethanol and randomization of object placement. Furthermore, 
increased statistical power in brain tissue analysis was needed to detect a significant 
effect, indicating that a slightly larger sample size could have improved our findings. This 
study is also limited by the fact that only cerebellar tissue was analyzed as other brain 
regions may be more or less susceptible to Aβ pathology.  
In this study we asked a fundamental question about the behavior of the Aβ 
protein and its processing in the brains of animals that received multiple mild TBIs. Our 
findings show a clear difference between animals in terms of cognitive performance on 
multiple behavioral tasks, with more deficits being detected in impacted hAPP mice. We 
were also able to show a trend of alterations in protein accumulation among impacted and 
sham hAPP mice. Future studies will likely include analysis of other brain regions in 
addition to the cerebellum, such as the cortex, hippocampus, and brainstem, which will be 
expected to reveal higher levels of relative Aβ in impacted animals. In addition to 
analyzing brain tissue in search of Aβ, levels of proteins that are known to break down 
Aβ, namely neprilysin, should also be examined as it is hypothesized that TBI may 
modulate levels of these proteins. The time frame in which Aβ acts to potentiate 
neurodegeneration or is involved in TBI recovery is another relevant question our model 
could contribute to answering as previous research has shown decreased Aβ accumulation 
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weeks after TBI (Nakagawa et al., 2000). Examining this question in addition to 
neprilysin-TBI interactions may lend insight into the mechanism by which Aβ and tau 
interact to potentiate disease as CTE research has shown that tau pathology is the primary 
disease culprit (Tagge et al., 2018). Additionally, to contribute to the validation of the 
current model system future studies should include analysis of glial activity following 
chronic impacts as human cases of TBI have shown patient brains exhibit elevated glial 
activity (Ramlackhansingh et al., 2011). Theoretically, a similar profile of glial activity 
would be seen in the model system presented. Furthermore, following a similar 
experimental procedure, tau pathology should be examined in relation to neprilysin and 
Aβ accumulation after TBI. Finally, experiments investigating pharmacological 
treatments could potentially be conducted using this model to contribute to a growing 
body of literature that is beginning to suggest promise in NMDA antagonists such as 
memantine as an effective post-TBI therapy (Kelestemur et al., 2016). Studies in this field 
are likely to reveal more insight into the signaling pathways involved in TBI and related 
disease pathology.     
 
Conclusion 
The results of our study are of critical value to the research community as the 
pathological effects of repeated TBI are not well understood, especially on the protein 
level. How TBI pathology progresses over time, in terms of behavioral and biochemical 
changes, in response to repeated TBI is also a question that the current study can lend 
insight into. With refinement of the paradigm presented, this model may be able to 
answer more questions involving the implications of Aβ processing in conjunction with 
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mild TBI. 
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Figures & Tables 
Table 1. Summary of Independent t-test Results 
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Figure 1. Experimental timeline 
The first of five impacts or sham procedures were administered to 7-8 week old non-
transgenic and hAPP mice beginning on day -8 to day 0. Behavioral tests began two hours 
after the final impact or sham procedure was delivered on day 0 with the rotarod 
assessment followed by a 30-minute open field (OF) test. Another rotarod assessment was 
administered 24-hours after the final impact/sham procedure which was followed by the 
habituation phase of the NOR test. At day 2, animals were exposed to a novel object. Day 
6 through 8 consisted of MWM acquisition trials. Probe test 1 was carried out on day 11 
and probe test 2 was conducted on day 13.   
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A. 
  
B. 
 
Figure 2. Total run time 2-hours and 24-hours post impact.   
A. Total run time on rotarod 2-hours post final impact or sham procedure revealed 
statistically significant differences in run-time within the hAPP genotype. Non-
transgenic mice showed no statistically significant differences in run time between 
impact and sham conditions. Mice with the hAPP transgene that received impacts 
performed significantly more poorly than mice that received sham procedures 
(p=.024). 
B. Total run time on rotarod 24-hours post final impact or sham procedure revealed 
statistically significant differences in total run-time of hAPP mice that received 
impacts versus sham procedures. Non-transgenic mice that received impacts 
showed no statistically significant differences in run time as compared to non-
transgenic sham mice. Mice with the hAPP transgene that received impacts 
AMYLOID-BETA AND REPEATED TBI 
 
 
46 
performed significantly more poorly than hAPP mice that received sham 
procedures (p=.006).  
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A. 
  
B. 
 
Figure 3. Open field tests of locomotion and anxiety. 
A. Within the hAPP genotype, mice that received sham procedures traveled a 
significantly further distance as compared to impacted hAPP mice (p=.009) 
indicating impaired locomotion. Non-transgenic mice showed no significant 
differences in distance traveled. 
B. Using time spent in the center of the open field as a traditional measure of anxiety 
revealed no significant differences across groups. 
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Figure 4. Novel object recognition memory assessment.  
No significant differences in time spent at either object were detected between groups. 
This indicates that mice did not recognize the novel object. Non-transgenic mice failing 
to show preference for the novel object may indicate a problem in methodology.    
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Figure 5. Morris water maze assessment of spatial learning and memory.  
Morris water maze revealed hAPP mice that received impacts performed significantly 
more poorly in time to reach platform than other groups. Both sham conditions 
outperformed impacted groups over the course of the five-day training period in time to 
reach platform. On day five, hAPP sham mice completed the maze significantly faster 
than impacted hAPP mice (p=.005), while non-transgenic sham mice similarly 
outperformed impacted non-transgenic mice (p=.041).  
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Figure 6. Water maze probe test 1 and 2. 
A. Probe test 1, carried out 24-hours after MWM acquisition training day 5 revealed 
that hAPP mice receiving sham procedures remained in the correct quadrant for a 
longer proportion of time as compared to all other groups. This indicates impaired 
memory among impacted mice.  
B. Probe test 2, carried out 72-hours after MWM acquisition day 5 revealed that 
sham mice spent more time in the correct quadrant than impacted mice. This 
indicated that impacts may impair memory.  
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Figure 7. Relative amyloid-beta levels post-impacts. 
No significant differences in cerebellar protein levels were detected between groups post 
impact using two-way analysis of variance tests. However, a student’s t-test revealed that 
impacted hAPP mice had significantly higher levels of relative Ab42 as compared to 
sham hAPP mice (p=.044). No significant differences were detected between treatment 
conditions within the non-transgenic cohort of mice.   
 
 
 
 
 
 
 
 
 
